Search Results - Tamika Allen
- Showing 1 - 4 results of 4
-
1
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo by Daniel J. Powell, Aloísio Felipe-Silva, Maria J. Merino, Mojgan Ahmadzadeh, Tamika Allen, Catherine Lévy, Donald E. White, Sharon Mavroukakis, Robert J. Kreitman, Steven A. Rosenberg, Ira Pastan
Published 2007Artigo -
2
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis by James Chih‐Hsin Yang, Marybeth S. Hughes, Udai S. Kammula, Richard E. Royal, Richard M. Sherry, Suzanne L. Topalian, Kimberly B. Suri, Catherine Lévy, Tamika Allen, Sharon Mavroukakis, Israel Lowy, Donald E. White, Steven A. Rosenberg
Published 2007Artigo -
3
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma by Ajay V. Maker, James Chih‐Hsin Yang, Richard M. Sherry, Suzanne L. Topalian, Udai S. Kammula, Richard E. Royal, Marybeth S. Hughes, Michael Yellin, Leah Haworth, Catherine Lévy, Tamika Allen, Sharon Mavroukakis, Peter Attia, Steven A. Rosenberg
Published 2006Artigo -
4
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade by Stephanie G. Downey, Jacob A. Klapper, Franz O. Smith, James Chih‐Hsin Yang, Richard M. Sherry, Richard E. Royal, Udai S. Kammula, Marybeth S. Hughes, Tamika Allen, Catherine Lévy, Michael Yellin, Geoffrey Nichol, Donald E. White, Seth M. Steinberg, Steven A. Rosenberg
Published 2007Artigo
Search Tools:
Related Subjects
Immune system
Immunology
Medicine
Cancer research
Gastroenterology
Immunotherapy
Internal medicine
Melanoma
Antibody
Cancer
Clinical trial
Ipilimumab
Oncology
T cell
Toxicity
Adverse effect
Biology
Biotechnology
Blockade
CD8
CTL*
CTLA-4
Clinical endpoint
Cohort
Common Terminology Criteria for Adverse Events
Concomitant
FOXP3
IL-2 receptor
Immunotoxin
In vivo